Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer

PPublication Type:

Article

Authors:

Guinevere G. Connelly, Orville O. Kirkland, Seven Bohannon, Daniel C. Lim, Robert M. Wilson, Edward J. Richards, Dousabel M. Tay, Hyuk Jee, Riley D. Hellinger, Ngoc K. Hoang, Liang Hao, Arnav Chhabra, Carmen Martin-Alonso, Edward K.W. Tan, Angela N. Koehler, Michael B. Yaffe, Wendy B. London, Pui Y. Lee, Florian Krammer, Robert C. Bohannon, Sangeeta N. Bhatia, Hadley D. Sikes, Hojun Li

Source:

Cell Reports Methods (2022)

URL:

https://www.sciencedirect.com/science/article/pii/S2667237522001503

Abstract:

Neutralizing antibody (NAb) titer is a key biomarker of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but point-of-care methods for assessing NAb titer are not widely available. Here, we present a lateral flow assay that captures SARS-CoV-2 receptor-binding domain (RBD) that has been neutralized from binding angiotensin-converting enzyme 2 (ACE2). Quantification of neutralized RBD in this assay correlates with NAb titer from vaccinated and convalescent patients. This methodology demonstrated superior performance in assessing NAb titer compared with either measurement of total anti-spike immunoglobulin G titer or quantification of the absolute reduction in binding between ACE2 and RBD. Our testing platform has the potential for mass deployment to aid in determining at population scale the degree of protective immunity individuals may have following SARS-CoV-2 vaccination or infection and can enable simple at-home assessment of NAb titer.

Manuscript (PDF)

Supporting information (Link)